DE60313593D1 - Chemische igf-i-zusammensetzung zur behandlung und prävention von neurodegenerativen erkrankungen - Google Patents

Chemische igf-i-zusammensetzung zur behandlung und prävention von neurodegenerativen erkrankungen

Info

Publication number
DE60313593D1
DE60313593D1 DE60313593T DE60313593T DE60313593D1 DE 60313593 D1 DE60313593 D1 DE 60313593D1 DE 60313593 T DE60313593 T DE 60313593T DE 60313593 T DE60313593 T DE 60313593T DE 60313593 D1 DE60313593 D1 DE 60313593D1
Authority
DE
Germany
Prior art keywords
prevention
treatment
igf
chemical
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60313593T
Other languages
English (en)
Other versions
DE60313593T2 (de
Inventor
Lopez C Lopez
Diaz E M Carro
Alem N I Torres
Duran J J Torrado
Duran S Torrado
Celia Carrascosa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Consejo Superior de Investigaciones Cientificas CSIC
Universidad Complutense de Madrid
Original Assignee
Consejo Superior de Investigaciones Cientificas CSIC
Universidad Complutense de Madrid
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Consejo Superior de Investigaciones Cientificas CSIC, Universidad Complutense de Madrid filed Critical Consejo Superior de Investigaciones Cientificas CSIC
Publication of DE60313593D1 publication Critical patent/DE60313593D1/de
Application granted granted Critical
Publication of DE60313593T2 publication Critical patent/DE60313593T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
DE60313593T 2002-02-28 2003-02-21 Chemische igf-i-zusammensetzung zur behandlung und prävention von neurodegenerativen erkrankungen Expired - Lifetime DE60313593T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ES200200491 2002-02-28
ES200200491A ES2207387B1 (es) 2002-02-28 2002-02-28 Composicion quimica de igf-i para el tratamiento y prevencion de enfermedades neurodegenerativas.
PCT/ES2003/000087 WO2003077940A1 (es) 2002-02-28 2003-02-21 Composicion quimica de igf-i para el tratamiento y prevencion de enfermedades neurodegenerativas

Publications (2)

Publication Number Publication Date
DE60313593D1 true DE60313593D1 (de) 2007-06-14
DE60313593T2 DE60313593T2 (de) 2008-01-31

Family

ID=27838351

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60313593T Expired - Lifetime DE60313593T2 (de) 2002-02-28 2003-02-21 Chemische igf-i-zusammensetzung zur behandlung und prävention von neurodegenerativen erkrankungen

Country Status (13)

Country Link
US (1) US20050208126A1 (de)
EP (1) EP1488801B1 (de)
JP (1) JP2005529083A (de)
AT (1) ATE361094T1 (de)
AU (1) AU2003209777B2 (de)
CA (1) CA2477593C (de)
DE (1) DE60313593T2 (de)
DK (1) DK1488801T3 (de)
ES (2) ES2207387B1 (de)
MX (1) MXPA04008402A (de)
PL (1) PL373382A1 (de)
PT (1) PT1488801E (de)
WO (1) WO2003077940A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2587601C (en) * 2004-12-03 2017-11-07 Rhode Island Hospital Diagnosis and treatment of alzheimer's disease
US7833513B2 (en) 2004-12-03 2010-11-16 Rhode Island Hospital Treatment of Alzheimer's Disease
WO2008111520A1 (ja) * 2007-03-09 2008-09-18 Nagasaki University 寿命延長関連遺伝子およびその用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4962091A (en) * 1986-05-23 1990-10-09 Syntex (U.S.A.) Inc. Controlled release of macromolecular polypeptides
US5093317A (en) * 1989-06-05 1992-03-03 Cephalon, Inc. Treating disorders by application of insulin-like growth factor
DK0659083T3 (da) * 1992-06-12 2000-06-13 Einstein Coll Med Forebyggelse og behandling af perifer neuropati
US5705197A (en) * 1994-05-16 1998-01-06 The United States Of America As Represented By The Secretary Of The Army Extraction process for producing PLGA microspheres
US5888551A (en) * 1995-12-11 1999-03-30 University Of Miami Hair growth stimulating composition
ES2158611T3 (es) * 1996-12-20 2001-09-01 Alza Corp Composicion en gel inyectable con efecto retard y procedimiento para la preparacion de dicha composicion.
JPH10273447A (ja) * 1997-01-29 1998-10-13 Takeda Chem Ind Ltd 徐放性マイクロスフィア、その製造法および用途
US5861149A (en) * 1997-06-04 1999-01-19 Polyheal Ltd. Methods for wound treatment
AU1384199A (en) * 1997-11-07 1999-05-31 Chiron Corporation Method for producing igf-1 sustained-release formulations
ES2146530B1 (es) * 1997-12-26 2001-04-16 Consejo Superior Investigacion Utilizacion del factor de crecimiento igf-i en la fabricacion de composiciones utiles en el tratamiento de la ataxia cerebelar.
WO2000040612A1 (en) * 1999-01-06 2000-07-13 Genentech, Inc. Insulin-like growth factor (igf) i mutant variants

Also Published As

Publication number Publication date
CA2477593A1 (en) 2003-09-25
WO2003077940A1 (es) 2003-09-25
PL373382A1 (en) 2005-08-22
CA2477593C (en) 2012-05-15
ES2207387A1 (es) 2004-05-16
EP1488801B1 (de) 2007-05-02
JP2005529083A (ja) 2005-09-29
DK1488801T3 (da) 2007-09-10
US20050208126A1 (en) 2005-09-22
AU2003209777B2 (en) 2008-01-10
ES2207387B1 (es) 2005-07-16
AU2003209777A1 (en) 2003-09-29
MXPA04008402A (es) 2005-07-27
EP1488801A1 (de) 2004-12-22
ATE361094T1 (de) 2007-05-15
PT1488801E (pt) 2007-08-14
DE60313593T2 (de) 2008-01-31
ES2287500T3 (es) 2007-12-16

Similar Documents

Publication Publication Date Title
ATE406893T1 (de) Pharmazeutische zusammensetzung (kit) enthaltend dihydropyridinonverbindungen und eine verbindung mit immunmodulatorischer (oder antiinflammatorischer) wirkung und ihre verwendung
ATE355374T1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
MY129422A (en) Medicinal compounds
TW200502221A (en) Novel lactams and uses thereof
TNSN04165A1 (en) Substituted hydroxyethylamines
SE0104340D0 (sv) New compounds
TW200420550A (en) Thiazole compounds for the treatment of neurodegenerative disorders
PT2527315E (pt) Compostos, composições e métodos para o tratamento de doenças da amiloide e sinucleínopatias tais como doença de alzheimer, diabetes do tipo 2, e doença de parkinson
CA2501799A1 (en) Pyrazole compounds for treatment of neurodegenerative disorders
HK1080764A1 (en) Implant for transport and release for pharmacologically active agents as well as a process for producing the same
TW200602297A (en) Sulfonamide compounds for the treatment of neurodegenerative disorders
ATE367387T1 (de) Verwendung von oxindolderivaten zur behandlung von mit demenz in zusammenhang stehenden krankheiten, alzheimer-krankheit und mit glycogensynthasekinase-3 assoziierten leiden
ATE439833T1 (de) Pharmazeutische zubereitung enthaltend ein catechin, ascorbinsäure, prolin und lysin zur behandlung von neoplastischen krankheiten
HK1104280A1 (en) Derivatives of 1-phenylalkanecarboxylic acids for the treatment of neurodegenerative diseases
ATE402150T1 (de) Pyrazolaminverbindungen zur behandlung neurodegenerativer erkrankungen
HK1079688A1 (en) Statin product for enhancing cognitive maintenance
ATE361094T1 (de) Chemische igf-i-zusammensetzung zur behandlung und prävention von neurodegenerativen erkrankungen
EP1201240A3 (de) Heterozyklische Verbindungen verwendbar als pharmazeutische Mittel
TW200504036A (en) Novel lactams and uses thereof
DE60231054D1 (de) Piperidinderivate, verfahren zu deren herstellung und pharmazeutische zusammensetzung zur behandlung von alzheimer-krankheit, die diese derivate enthält
PL1652836T3 (pl) Diamidy nie-α-aminokwasów użyteczne jako środki wspomagające do podawania środków biologicznie czynnych
BRPI0509881A (pt) combinação terapêutica para tratamento da doença de alzheimer
TW200509915A (en) Novel oxazoles, their manufacture and use as pharmaceutical agents
SE0302666D0 (sv) Novel Compounds

Legal Events

Date Code Title Description
8364 No opposition during term of opposition